2 hours ago
1
- Sana Biotechnology press release (NASDAQ:SANA): Q2 Non-GAAP EPS of -$0.39.
- Cash, cash equivalents, and marketable securities as of June 30, 2025 were $72.7 million compared to $152.5 million as of December 31, 2024. The decrease of $79.8 million was primarily driven by cash used in operations of $81.8 million.
More on Sana Biotechnology
- Sana Biotechnology: Fundraising Triggers Major Sell-Off, I'm Still Intrigued
- Sana: HIP-Modified Islet Cells To Possibly Change Scope Of Type 1 Diabetes Treatment
- Sana Biotechnology drops 13% on $75M stock issuance, prices at $3.35
- Seeking Alpha’s Quant Rating on Sana Biotechnology
- Historical earnings data for Sana Biotechnology
English (US) ·